Related Experiment Videos
[Cardiogenic shock following acute myocardial infarction. Pathophysiology and clinical aspects (author's transl)]
Insights
Cardiogenic shock, often stemming from myocardial infarction, impairs left ventricle function, leading to poor circulation and metabolic acidosis. Interventions like intra-aortic balloon pumps can significantly reduce mortality.
Area of Science:
- Cardiology
- Critical Care Medicine
Context:
- Cardiogenic shock is a severe complication of extensive myocardial infarction.
- It involves left ventricular failure, leading to microcirculation disturbances and metabolic acidosis.
Purpose:
- To describe the pathophysiology and clinical presentation of cardiogenic shock.
- To outline current therapeutic strategies and their impact on mortality.
Summary:
- Cardiogenic shock originates from myocardial infarction, causing left ventricular failure, reduced peripheral circulation, and metabolic acidosis.
- Clinical signs include hypotension, oliguria, and clammy skin.
- Treatment with intra-aortic balloon counter-pulsation and cardiosurgery has decreased mortality rates.
Impact:
- Therapeutic interventions have improved survival rates for cardiogenic shock patients.
- Highlights the importance of timely and aggressive treatment for acute myocardial infarction complications.
Abstract:
The starting point of cardiogenic shock is an extensive myocardial infarction. Through a backward and forward failure of the left ventricle a shock-specific disturbance of the microcirculation occurs with a reduction of the circulation in the periphery of the body and development of a tissue acidosis (metabolic acidosis). Fall in blood pressure and cardiac volume, congestion of blood in the region of the pulmonary vessels and signs of reduced circulation in the body periphery (severe physical weakness, apathy, cold and clammy skin, oliguria) determine the clinical picture of cardiogenic shock. Therapeutically, intra-aortal balloon counter-pulsation, possibly combined with a cardiosurgical intervention, has reduced the mortality of cardiogenic shock after acute myocardial infarction from 90--100% to 60--70%.